



26 October 2020

Novartis Pharma AG
Basel, Switzerland
CH-4002

Reference: EudraCT 2017-002741-29 Novartis Protocol ID CMAA868A2202.

A multicenter, randomized, open-label, active-controlled, dose-range finding study to assess the pharmacodynamic parameters, safety and tolerability of MAA868 and its effect on thrombogenesis biomarkers compared to apixaban in patients with atrial fibrillation.

Trial 2017-002741-29 was cancelled with no patient enrollment and as such, no results will be reported.